An inhaled insulin device created by MannKind Corp proved to be more effective than oral treatments or injections, a source told Reuters.
The product called Afrezza is a small-sized inhaler that provides powdered insulin to adults suffering from Type 1 and Type 2 diabetes.
According to Reuters, the said medication may be more effective compared to other types because it is easier to use.
According to a report presented by the Transparency Market Research, the number of patients suffering from diabetes will increase at up to 500,000 by 2030.
Graig Suvannavejh, analyst at MLV & Co told Reuters that they expect Afrezza to receive regulatory approval.
He expressed that as of late, this is not the company's biggest concern; rather they are more concerned whether not they can successfully commercialize the product.
Suvannavejh told Reuters that the commercialization of this product will require heavy lifting and extensive education.
He also estimated the sales of the Afrezza to reach $3 billion by 2025.
According to Reuters, Afrezzs is the flagship product of MannKind who have increased their shares nearly 50% over the past three months due to the positive data they gathered from two trials.
Results of the two studies showed reduced fasting blood glucose levels and lower chances of acquiring hypoglycemia.
MannKind told Reuters that they expect to submit the results of their study to the U.S Food and Drug Administration during the fourth quarter of the year which will end in December.
